Another day, another cancer immunotherapy alliance, and this time it’s Roche and India’s Curadev Pharma shaking on a $555-million-plus deal to develop and commercialise IDO1 and TDO inhibitors. 

IDO1 (indoleamine-2, 3-dioxygenase-1) and TDO (tryptophan-2, 3-dioxygenase) are enzymes that mediate cancer-induced immune suppression. Dual inhibition of these pathways has shown promise in maintaining the immune response and preventing local tumours from immune escape, and could also help avoid resistance to other immunotherapies when used in combination with other drugs, according to Curadev. 

Under the deal, Roche is paying $25 million upfront and $530 million in milestones for access to Curadev's lead candidate, which the New Delhi-based firm says could work as a monotherapy as well as in combination with Roche's cancer drugs.

The deal also covers collaborative research and early development to further examine the IDO and TDO pathways. Roche will fund future research, development, manufacturing and commercialisation costs and will also provide additional research funding to Curadev for support of the research collaboration.